-
TCAIM Controls OGDH Abundance and Mitochondrial Metabolism
2026-09-28
Wang and colleagues identify the mitochondrial DNAJC co-chaperone TCAIM as a specific binding partner of OGDH that promotes its reduction through HSPA9 and LONP1. The work links mitochondrial protein quality control to OGDH complex activity and carbohydrate catabolism, while highlighting a regulatory role for a co-chaperone beyond conventional protein folding.
-
HMGCS2 Loss and Lipid Signaling in Pulmonary Fibrosis
2026-09-27
Yang et al. connect reduced HMGCS2 in injured alveolar type II epithelial cells with altered lipid handling and LysoPC-associated fibroblast activation in experimental pulmonary fibrosis. Their cell and mouse experiments suggest an epithelial HMGCS2–PPARα–CPT1A/CPT2 axis that may limit fibrotic progression, while leaving important questions about specific lipid species and human disease unresolved.
-
GSK3 Inhibition Restricts Intracellular Tuberculosis
2026-09-26
The study identifies glycogen synthase kinase 3 (GSK3) as a host-cell pathway that supports intracellular Mycobacterium tuberculosis growth and shows that pharmacological and genetic inhibition can reduce that growth in human macrophage models. Its findings support further investigation of host-directed therapy, while leaving efficacy, safety, and treatment value to be established in vivo and clinically.
-
FK866 (APO866): Translating NAD Biology into Strategy
2026-09-26
NAMPT inhibition offers a way to test how NAD availability shapes cancer-cell fitness. This article connects FK866 (APO866) research in hematologic malignancies with findings on NAD-associated PARP inhibitor resistance in ovarian cancer—while distinguishing mechanistic rationale from evidence of efficacy.
-
ML385 Workflows for NRF2 Pathway Research
2026-09-25
Use ML385 to test whether NRF2 activity contributes to antioxidant defenses, ferroptosis-associated readouts, or cancer therapeutic resistance—not merely whether a treatment changes viability. This guide connects non-small cell lung cancer research with a cited alcoholic liver injury study and offers practical dose-finding, controls, and troubleshooting steps.
-
Sodium chloride B7288: Preparation and QC
2026-09-25
Sodium chloride B7288 is an inorganic salt for adjusting ionic strength and supporting osmotic balance in aqueous buffers, biochemical assays, and cell culture media formulations. Use it when a defined NaCl contribution is needed; do not use it as a pH buffer or assume the supplied solid or a prepared solution is sterile or suitable for long-term storage.
-
IR-1061 for NIR-II Imaging Workflows
2026-09-24
IR-1061 is a near infrared fluorescent dye for deep-tissue optical studies, with practical handling shaped by its strong DMSO solubility and poor water compatibility. This guide translates a published ultrasound-enhanced nanocatalysis study into a careful imaging workflow—while distinguishing what the paper demonstrated from starting conditions researchers should validate themselves.
-
Omeprazole A2845: Research Workflow and QC
2026-09-24
Omeprazole (A2845) provides a research reagent for investigating H+,K+-ATPase inhibition and gastric acid secretion, with dossier-reported activity values to guide assay planning. It is for laboratory research only—not diagnostic, therapeutic, or clinical use—and the listed chemical identity should be checked against current lot documentation before mechanism-specific conclusions are drawn.
-
Huangqin Decoction and the Microbiota–AhR Repair Axis
2026-09-23
Li et al. identify a microbiota–tryptophan metabolism–AhR–intestinal stem cell axis that links Huangqin decoction with epithelial repair in a dextran sulfate sodium model of ulcerative colitis. The study combines microbiome, metabolite, receptor, inflammatory, and stem-cell analyses, while antibiotic and AhR-inhibition experiments provide evidence that this pathway is functionally important rather than merely correlative.
-
SR-202: Selective PPARγ Antagonist
2026-09-22
SR-202 is a selective PPARγ antagonist that blocks TZD-associated coactivator recruitment and transcriptional activity. Product data support its use in adipogenesis, insulin resistance research, obesity research, and type 2 diabetes research, while peer-reviewed evidence separately shows that PPARγ activation can regulate macrophage polarization.
-
Probenecid Workflows for MDR and Neuroprotection
2026-09-22
Probenecid provides a practical way to interrogate MRP-mediated drug efflux, pannexin-1 activity, and injury-associated inflammatory responses in complementary experimental systems. This workflow-focused guide combines transporter assays, chemotherapy sensitization, cerebral ischemia/reperfusion models, and immunometabolic assay design with troubleshooting guidance.
-
Minocycline HCl in EV and Inflammation Workflows
2026-09-21
Minocycline HCl can serve as an anti-inflammatory comparator, mechanistic probe, and neuroprotection tool alongside scalable mesenchymal stem cell extracellular vesicle workflows. This guide connects compound handling with EV quality control, assay design, troubleshooting, and translational limitations.
-
Phosphatase Inhibitor Cocktail 2 Workflow
2026-09-21
Protect phosphorylation-dependent biology from the moment tissue or cells are lysed through Western blotting, co-immunoprecipitation, imaging, and kinase assays. This workflow shows how a 100X, broad-spectrum formulation can improve sample fidelity while connecting phosphoprotein handling to new SIRT6–proteostasis research.
-
EV-Transferred ACLY Drives TAMs in HCC
2026-09-20
The reference study identifies extracellular vesicle delivery of ATP-citrate lyase (ACLY) as a metabolic mechanism that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its CD81-decorated liposomal vesicle experiments further suggest that selectively blocking ACLY cargo in monocytes can reduce tumor-promoting macrophage activity and improve responses to PD-1/PD-L1 blockade.
-
Standardized Amplex Red Assay for Autotaxin Inhibitors
2026-09-19
The 2025 STAR Protocols paper establishes a fluorometric microplate workflow for screening and characterizing autotaxin inhibitors through an enzyme-coupled Amplex Red reaction. Its main contribution is an integrated strategy that progresses from primary screening to IC50 measurement, false-positive exclusion, and kinetic analysis of inhibitor mechanism.